BACKGROUND & AIMS: Small intestinal cancer (SIC) is rare, and its etiology is poorly understood. We compared clusters of families with SICs of different histologic subtypes. METHODS: By using the nationwide family cancer data sets of Sweden and Finland, we identified a cohort of 9964 first-degree relatives of 1799 patients with SIC, diagnosed from 1961 through 2009. Data were collected from time periods as long as 47 years (mean, 35.4 y), and cancer incidence was determined. Standardized incidence ratios (SIRs) were calculated and stratified by sex, age, time period, and cancer type, using the incidence rates for the entire national population as the reference. RESULTS: Among the 1799 SIC cases, 1.1% had a sibling with SIC, so the SIR was 11.8 (95% confidence interval [CI], 7.2-18.2); 1.1% had a parent or child with SIC (SIR, 3.5; 95% CI, 2.0-5.6). The SIR of concordant carcinoid histology of SIC among siblings was 28.4 (95% CI, 14.7-49.6; n = 12) and in parent-child pairs was 9.9 (95% CI, 5.4-16.6; n = 14). The familial risk of concordant histologic subtypes increased for siblings diagnosed with adenocarcinoma, but only 2 familial cases were identified. In family members of patients with SIC of the adenocarcinoma subtype, risks of colorectal and bladder cancer were modestly but significantly increased compared with the general population. Family members of patients with SIC of the carcinoid subtype had an increased risk for kidney cancer and polycythemia vera. CONCLUSIONS: Based on data from our population-based study, first-degree relatives of patients with small intestinal carcinoid tumors have developed these tumors with high incidence. Because of the rareness of this tumor, the absolute risk remains moderate even within families. Gastroenterologists could inform patients with small intestinal carcinoids about the familial risk and encourage counseling for their first-degree relatives. Studies are needed to identify genetic factors that affect susceptibility to SIC.
BACKGROUND & AIMS: Small intestinal cancer (SIC) is rare, and its etiology is poorly understood. We compared clusters of families with SICs of different histologic subtypes. METHODS: By using the nationwide family cancer data sets of Sweden and Finland, we identified a cohort of 9964 first-degree relatives of 1799 patients with SIC, diagnosed from 1961 through 2009. Data were collected from time periods as long as 47 years (mean, 35.4 y), and cancer incidence was determined. Standardized incidence ratios (SIRs) were calculated and stratified by sex, age, time period, and cancer type, using the incidence rates for the entire national population as the reference. RESULTS: Among the 1799 SIC cases, 1.1% had a sibling with SIC, so the SIR was 11.8 (95% confidence interval [CI], 7.2-18.2); 1.1% had a parent or child with SIC (SIR, 3.5; 95% CI, 2.0-5.6). The SIR of concordant carcinoid histology of SIC among siblings was 28.4 (95% CI, 14.7-49.6; n = 12) and in parent-child pairs was 9.9 (95% CI, 5.4-16.6; n = 14). The familial risk of concordant histologic subtypes increased for siblings diagnosed with adenocarcinoma, but only 2 familial cases were identified. In family members of patients with SIC of the adenocarcinoma subtype, risks of colorectal and bladder cancer were modestly but significantly increased compared with the general population. Family members of patients with SIC of the carcinoid subtype had an increased risk for kidney cancer and polycythemia vera. CONCLUSIONS: Based on data from our population-based study, first-degree relatives of patients with small intestinal carcinoid tumors have developed these tumors with high incidence. Because of the rareness of this tumor, the absolute risk remains moderate even within families. Gastroenterologists could inform patients with small intestinal carcinoids about the familial risk and encourage counseling for their first-degree relatives. Studies are needed to identify genetic factors that affect susceptibility to SIC.
Authors: Karen Curtin; Lisa A Cannon-Albright; James VanDerslice; Zhe Yu; Kimberly A Herget; Ramya Thota; Deborah W Neklason Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-09-26 Impact factor: 4.254
Authors: Yoshitatsu Sei; Xilin Zhao; Joanne Forbes; Silke Szymczak; Qing Li; Apurva Trivedi; Mark Voellinger; Grishma Joy; Jianying Feng; Millie Whatley; MaryPat Sussex Jones; Ursula L Harper; Stephen J Marx; Aradhana M Venkatesan; Settara C Chandrasekharappa; Mark Raffeld; Martha M Quezado; Adeline Louie; Clara C Chen; Ramona M Lim; Richa Agarwala; Alejandro A Schäffer; Marybeth S Hughes; Joan E Bailey-Wilson; Stephen A Wank Journal: Gastroenterology Date: 2015-04-09 Impact factor: 22.682
Authors: Yeting Du; Monica Ter-Minassian; Lauren Brais; Nichole Brooks; Amanda Waldron; Jennifer A Chan; Xihong Lin; Peter Kraft; David C Christiani; Matthew H Kulke Journal: Endocr Relat Cancer Date: 2016-08 Impact factor: 5.678
Authors: Deborah W Neklason; James VanDerslice; Karen Curtin; Lisa A Cannon-Albright Journal: Endocr Relat Cancer Date: 2015-11-24 Impact factor: 5.678
Authors: Marybeth S Hughes; Saïd C Azoury; Yasmine Assadipour; David M Straughan; Apurva N Trivedi; Ramona M Lim; Grishma Joy; Mark T Voellinger; Derek M Tang; Aradhana M Venkatesan; Clara C Chen; Adeline Louie; Martha M Quezado; Joanne Forbes; Stephen A Wank Journal: Surgery Date: 2015-10-09 Impact factor: 3.982
Authors: Dirk Walter; Patrick N Harter; Florian Battke; Ria Winkelmann; Markus Schneider; Katharina Holzer; Christine Koch; Jörg Bojunga; Stefan Zeuzem; Martin Leo Hansmann; Jan Peveling-Oberhag; Oliver Waidmann Journal: Sci Rep Date: 2018-02-28 Impact factor: 4.379
Authors: James VanDerslice; Marissa C Taddie; Karen Curtin; Caroline Miller; Zhe Yu; Rachael Hemmert; Lisa A Cannon-Albright; Deborah W Neklason Journal: PLoS One Date: 2020-04-23 Impact factor: 3.240
Authors: Yunxia Lu; Amanda J Cross; Neil Murphy; Heinz Freisling; Ruth C Travis; Pietro Ferrari; Verena A Katzke; Rudolf Kaaks; Åsa Olsson; Ingegerd Johansson; Frida Renström; Salvatore Panico; Valeria Pala; Domenico Palli; Rosario Tumino; Petra H Peeters; Peter D Siersema; H B Bueno-de-Mesquita; Antonia Trichopoulou; Eleni Klinaki; Christos Tsironis; Antonio Agudo; Carmen Navarro; María-José Sánchez; Aurelio Barricarte; Marie-Christine Boutron-Ruault; Guy Fagherazzi; Antoine Racine; Elisabete Weiderpass; Marc J Gunter; Elio Riboli Journal: Cancer Causes Control Date: 2016-06-13 Impact factor: 2.506